Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aravis Strengthens Life Science Team with Three Important Appointments

Published: Friday, January 10, 2014
Last Updated: Thursday, January 09, 2014
Bookmark and Share
Dr Dani Bach (formerly of Index Ventures) joins as Managing Partner, Dr Jacques Mizrahi joins in a consulting role as Venture Partner and Kadri Vunder (formerly LSVenture) as a Partner.

Aravis has announced the appointment of three new members of the life science investment team.

Dr Dani Bach joins Aravis in February 2014 as Managing Partner within the life science team. Dani was previously part of the life sciences team at Geneva based venture fund, Index Ventures, having joined the firm in 2007.

Dani’s investment interests have focused on protein therapeutics, neurodegeneration, and medical devices. Prior to joining Index, Dani held a research position at the Ecole Polytechnique Federal de Lausanne (EPFL), where he worked on the complex interactions between human immunodeficiency virus (HIV) and the human immune system. Dani holds a PhD in Molecular Biology from the University of Barcelona.

Dr Jacques Mizrahi began consulting Aravis as a Venture Partner in mid-2013. Dr Mizrahi has over 20 years of experience in drug discovery, drug development and translational medicine for many large pharma companies including Roche where his last position was as an Executive Leader, Cardiovascular & Metabolic Diseases. He has a PhD in pharmacology from Sherbrooke University, Quebec Canada.

Dr Kadri Vunder joined Aravis’ life science team as a Partner mid-2013. Dr. Vunder has over 10 years investment and executive management experience in the biotech, chemical and financial industries. Prior to joining Aravis, Kadri built up and managed a biotechnology oriented seed investment firm LSVenture.

Kadri holds a PhD in Economics from the University of St. Gallen and scientific degrees from the Tallinn Technical University in Biotechnology and Analytical Chemistry.

Dr Simon Nebel, Founder and Managing Partner at Aravis said :“2014 will be an important year for us and we are excited to be starting it with the appointment of these high caliber team members. I am confident that their deep knowledge and proven expertise in the life science sector will be advantageous for Aravis’ future enterprises.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Nanoparticles Target, Transform Fat Tissue
Nanoparticles designed to target white fat and convert it to calorie-burning brown fat slowed weight gain in obese mice without affecting food intake. This proof-of-concept work could lead to new therapies to treat obesity.
New Cancer Fighters Emerge From Lab
Rice University lab simplifies total synthesis of anti-cancer agent.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!